This issue can be addressed by genetically fusion of HER2-specific affibody molecule to the albumin-binding domain (ABD) that results in extension of affibody half-life and induction of antitumor effect in a micrometastatic model of breast cancer [112]. This evidence concerns the gene ERBB2 and breast cancer.